Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Premature ovarian failure protein 1B (POF1B) is an actin-binding protein encoded by the POF1B gene on the X chromosome, primarily expressed in polarized epithelial tissues and localized to tight junctions and desmosomes. It regulates epithelial monolayer organization through control of the actin cytoskeleton and is essential for tight junction and desmosome assembly, cell polarity, and tissue architecture in epithelia. Genetic variants in POF1B (e.g. R329Q) have been associated with the pathogenesis of premature ovarian failure, likely through impaired binding to nonmuscle actin filaments and altered cytoskeletal dynamics. Its disruption leads to defects in cell adhesion, polarity, and possibly increased ovarian germ-cell apoptosis, resulting in depletion of the ovarian reserve and clinical POF. POF1B is not currently a therapeutic target, and no drugs or small molecules are known to interact with its protein product.
None reported. No drugs known to target or modulate POF1B
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Premature ovarian failure protein 1B (POF1B).